UNITY Biotechnology
South San Francisco
About UNITY Biotechnology
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $294.9M
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2023)
- Ticker: nasdaq:UBX
- Website: unitybiotechnology.com
- Phone: +1 617 563 5800
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/unity-biotechnology-34662 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.